TY - JOUR
T1 - Evaluation of treatment response in patients with metastatic renal cell carcinoma
T2 - Role of state-of-the-art cross-sectional imaging
AU - Katabathina, Venkata S.
AU - Lassau, Nathalie
AU - Pedrosa, Ivan
AU - Ng, Chaan S.
AU - Prasad, Srinivasa R.
N1 - Funding Information:
Disclosures V. S. Katabathina: none. Dr. Nathalie Lassau has received honoraria from Pfizer, Bracco Imaging, Toshiba, Novartis, and Hoffman-La Roche. Dr. Ivan Pedrosa has received grants from Pfizer, GlaxoSmithKline, and Amgen. C. S. Ng: none; S. R. Prasad: none.
PY - 2012/2
Y1 - 2012/2
N2 - Recent advances in genetics and oncology have led to development of a wide array of molecular therapeutics in the management of patients with metastatic renal cell carcinoma. These drugs have revolutionized the treatment of advanced disease by significantly improving patient outcomes. State-of-the-art cross-sectional imaging techniques play a seminal role in the evaluation of treatment response by providing reproducible, objective data, thereby permitting accurate quantification of tumor burden. Evolving functional imaging techniques such as perfusion and diffusion studies continue to advance the technology beyond assessing changes in tumor size and morphology.
AB - Recent advances in genetics and oncology have led to development of a wide array of molecular therapeutics in the management of patients with metastatic renal cell carcinoma. These drugs have revolutionized the treatment of advanced disease by significantly improving patient outcomes. State-of-the-art cross-sectional imaging techniques play a seminal role in the evaluation of treatment response by providing reproducible, objective data, thereby permitting accurate quantification of tumor burden. Evolving functional imaging techniques such as perfusion and diffusion studies continue to advance the technology beyond assessing changes in tumor size and morphology.
KW - Arterial spin labeling
KW - Computed tomography
KW - Contrast-enhanced imaging
KW - Functional imaging techniques
KW - Magnetic resonance imaging
KW - Metastatic renal cell carcinoma
KW - Molecular therapeutics
KW - Positron emission tomography
KW - RECIST
KW - Treatment response
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=84857635197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857635197&partnerID=8YFLogxK
U2 - 10.1007/s11934-011-0233-x
DO - 10.1007/s11934-011-0233-x
M3 - Article
C2 - 22143974
AN - SCOPUS:84857635197
SN - 1527-2737
VL - 13
SP - 70
EP - 81
JO - Current urology reports
JF - Current urology reports
IS - 1
ER -